Ferring Adds Karolinska's Microbiome Expertise To Research Efforts
This article was originally published in Scrip
Executive Summary
The GI-focused privately held Swiss company Ferring Pharmaceuticals has moved more extensively into the hot microbiome research area by announcing plans to set up a microbiome translation research program in a strategic collaboration with Sweden's Karolinska Institute, whose research teams have a long history of studying bacterial populations.
You may also be interested in...
Ferring Looks For Early Microbiome Wins, But Willing To Do Heavy Lifting
Switzerland’s Ferring is diving deep into the microbiome, looking at a range of potential therapy platforms including bacteriophage and probiotics. Its CSO believes a microbiome-based therapeutic approach could benefit dermatological and women’s health conditions, as well as gastro-intestinal disorders.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.